Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LTI-03 in healthy volunteers
NCT04233814Phase 1Completed
- Sponsor
- Rein Therapeutics
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) (9 arms), sponsored by Rein Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 49 days. Started Jan 2020; status: completed.
02
Drugs
LTI-03
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04233814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233814.